(Q34289958)

English

Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

experimental infection

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Marta Gontijo Aguiar

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Aline Márcia Machado Pereira

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Ana Paula Fernandes

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Lucas Antonio Miranda Ferreira

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

16 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

4699-4704

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

Treatment of leishmaniasis with miltefosine: 2008 status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

Cutaneous leishmaniasis treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

Drug resistance in leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

In vitro and in vivo interactions between miltefosine and other antileishmanial drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

Clinical status of agents being developed for leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

Topical treatment for cutaneous leishmaniasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

The sensitivity of Leishmania species to aminosidine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

Different patterns of disease in two inbred mouse strains infected with a clone of Leishmania mexicana amazonensis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

6 July 2018

Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

28 October 2018

Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

28 October 2018

Effect of a hydrophilic formulation of topical paromomycin on cutaneous leishmaniasis among patients with contraindications for treatment with pentavalent antimonials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

28 October 2018

Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

28 October 2018

Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

28 October 2018

Miltefosine for new world cutaneous leishmaniasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

28 October 2018

Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

28 October 2018

In vivo interference of paromomycin with mitochondrial activity of Leishmania.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2976108

28 October 2018

Different Leishmania species determine distinct profiles of immune and histopathological responses in CBA mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20713665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distribution and metabolism of hexadecylphosphocholine in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/20713665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/20713665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20713665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20713665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.00809-10

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

release_y2optkradzhglk2pta4p6lxly4

1 reference

https://api.fatcat.wiki/v0/release/y2optkradzhglk2pta4p6lxly4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34289958&oldid=1844339515"